Acute drug-induced tubulointerstitial nephritis

Cover Page


Cite item

Full Text

Abstract

Currently, medications have the leading position in the development of acute tubulointerstitial nephritis. Antibiotics, proton pump inhibitors and non-steroidal anti-inflammatory drugs are the most common etiologic agents of acute tubulointerstitial nephritis. Various drugs produce ambiguous types of immune response. For instance, antibiotics may induce a systemic allergic reaction, including fever, skin rash, eosinophilia and arthralgia, whereas non-steroidal anti-inflammatory drugs and proton pump inhibitors may evoke a subclinical cell-modified response. Blood and urine tests, as well as renal ultrasound examination do not allow establishing a highly reliable diagnosis of acute tubulointerstitial nephritis. Therefore, renal biopsy is essential for the diagnosis. Morphological abnormalities include interstitial inflammation and tubulitis. In a patient who is on any medication and is having high serum creatinine levels, decreased glomerular filtration rate, and urine test abnormalities, the possibility of acute tubulointerstitial nephritis should be considered by the clinician; the disease can manifest at various time intervals after intake of the drug (from several days to months). Treatment approach is based first of all on immediate withdrawal of the nephrotoxic agent and possible administration of immunosuppressive therapy. Timely diagnosis and early administration of glucocorticoids in morphologically confirmed tubulointerstitial nephritis are critical for restoration of the kidney functioning. Chronic kidney disease can develop in some patients. Clinicians in any specialty have to know about potential negative consequences of the use of antibiotics, non-steroidal anti-inflammatory drugs, proton pump inhibitors and other medications and to consider nephrotoxic factors. 

About the authors

A. I. Dyadyk

M. Gorky Donetsk National Medical University

Email: fake@neicon.ru

MD, PhD, Professor, Head of Chair of Therapy, Faculty of Postgraduate Education

16 Illicha av., Donetsk, 83003

Украина

T. E. Kugler

M. Gorky Donetsk National Medical University

Author for correspondence.
Email: kugler2@mail.ru

MD, PhD, Assistant of Chair of Therapy, Faculty of Postgraduate Education

Tel.: +38050 141 40 80

16 Illicha av., Donetsk, 83003

Украина

References

  1. Mehta RL, Awdishu L, Davenport A, Murray PT, Macedo E, Cerda J, Chakaravarthi R, Holden AL, Goldstein SL. Phenotype standardization for drug-induced kidney disease. Kidney Int. 2015;88(2):226–34. doi: 10.1038/ki.2015.115.
  2. Izzedine H, Perazella MA. Anticancer drug-induced acute kidney injury. Kidney Int Rep. 2017;2(4):504–14. doi: 10.1016/j. ekir.2017.02.008.
  3. Kelly C, Neilson E. Tubulointerstitial diseases. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu AS. Brenner and Rector's the Kidney. 10th edition. Elsevier; 2016. p. 1209–30.
  4. Izzedine H, Guetin V. Drug-induced acute tubulointerstitial nephritis. In: Turner NN, Lameire N, Goldsmith DJ, Winearls CG, Himmelfarb J, Remuzzi G, Bennet WG, de Broe ME, Chapman JR, Covic A, Jha V, Sheerin N, Unwin R, Woolf A, editors. Oxford Textbook of Clinical Nephrology. 4th edition. Oxford University Press; 2016. p. 679–86. doi: 10.1093/ med/9780199592548.001.0001.
  5. Nast CC. Medication-induced interstitial nephritis in the 21st century. Adv Chronic Kidney Dis. 2017;24(2):72–9. doi: 10.1053/j. ackd.2016.11.016.
  6. Baker R. Acute tubulointerstitial nephritis: overview. In: Turner NN, Lameire N, Goldsmith DJ, Winearls CG, Himmelfarb J, Remuzzi G, Bennet WG, de Broe ME, Chapman JR, Covic A, Jha V, Sheerin N, Unwin R, Woolf A, editors. Oxford Textbook of Clinical Nephrology. 4th edition. Oxford University Press; 2016. p. 669–77. doi: 10.1093/ med/9780199592548.001.0001.
  7. Brodsky S, Nadasdy T. Acute and chronic tubulointerstitial nephritis. In: Jennette C, D'Agati V, Olson J, Silva F. Heptinstall’s Pathology of the Kidney. 7th edition. Wolters Kluwer; 2014. p. 1111–65.
  8. Громыко ВН, Пилотович ВС. Лекарственные нефропатии. Медицинские новости. 2016;(6):49–52.
  9. Blowey DL. Nephrotoxicity of over-the-counter analgesics, natural medicines, and illicit drugs. Adolesc Med Clin. 2005;16(1):31–43.
  10. Clarkson MR, Giblin L, O'Connell FP, O'Kelly P, Walshe JJ, Conlon P, O'Meara Y, Dormon A, Campbell E, Donohoe J. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004;19(11):2778–83. doi: 10.1093/ndt/ gfh485.
  11. Пентюк ОО, Волощук НІ, Машевська ОВ. Нефротоксичність лікарських засобів: клінічні прояви, патофізіологічні механізми та підходи до лікування. Раціональна фармакотерапія. 2009;(1):21–7.
  12. Krishnan N, Perazella MA. Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment. Iran J Kidney Dis. 2015;9(1): 3–13.
  13. Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2004;19(1):8–11. doi: 10.1093/ndt/ gfg464.
  14. Shirali A, Perazella M. Drug-induced nephropathies. In: Turner NN, Lameire N, Goldsmith DJ, Winearls CG, Himmelfarb J, Remuzzi G, Bennet WG, de Broe ME, Chapman JR, Covic A, Jha V, Sheerin N, Unwin R, Woolf A, editors. Oxford Textbook of Clinical Nephrology. 4th edition. Oxford University Press; 2016. p. 2885–910. doi: 10.1093/med/9780199592548.001.0001.
  15. Pai AB. Keeping kidneys safe: the pharmacist's role in NSAID avoidance in high-risk patients. J Am Pharm Assoc (2003). 2015;55(1):e15–23. doi: 10.1331/JAPhA.2015.15506.
  16. Naqvi R, Mubarak M, Ahmed E, Akhtar F, Naqvi A, Rizvi A. Acute tubulointerstitial nephritis/drug induced acute kidney injury; an experience from a single center in Pakistan. J Renal Inj Prev. 2016;5(1):17–20. doi: 10.15171/ jrip.2016.04.
  17. Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol. 2006;4(5):597–604. doi: 10.1016/j. cgh.2005.11.004.
  18. Rossert J, Fischer E. Acute interstitial nephritis. In: Johnson RJ, Feehally J, editors. Comprehensive clinical nephrology. St Louis: Mosby; 2000. p. 62.1–62.9.
  19. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461–70. doi: 10.1038/nrneph.2010.71.
  20. Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int. 1989;35(5):1257– 70. doi: 10.1038/ki.1989.118.
  21. Chang C, Gershwin ME. Drugs and autoimmunity – a contemporary review and mechanistic approach. J Autoimmun. 2010;34(3):J266–75. doi: 10.1016/j.jaut.2009.11.012.
  22. McCluskey RT, Colvin RB. Immunologic aspects of renal tubular and interstitial diseases. Annu Rev Med. 1978;29:191–203. doi: 10.1146/annurev.me.29.020178.001203.
  23. Kurts C. Dendritic cells: not just another cell type in the kidney, but a complex immune sentinel network. Kidney Int. 2006;70(3):412–4. doi: 10.1038/sj.ki.5001613.
  24. Rees A. Cross dendritic cells anger T cells after kidney injury. J Am Soc Nephrol. 2009;20(1): 3–5. doi: 10.1681/ASN.2008111200.
  25. Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD. Antigen presentation by dendritic cells in renal lymph nodes is linked to systemic and local injury to the kidney. Kidney Int. 2005;68(3):1096–108. doi: 10.1111/j.1523-1755.2005.00502.x.
  26. Soos TJ, Sims TN, Barisoni L, Lin K, Littman DR, Dustin ML, Nelson PJ. CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int. 2006;70(3):591–6. doi: 10.1038/sj.ki.5001567.
  27. Rogers NM, Ferenbach DA, Isenberg JS, Thomson AW, Hughes J. Dendritic cells and macrophages in the kidney: a spectrum of good and evil. Nat Rev Nephrol. 2014;10(11):625–43. doi: 10.1038/nrneph.2014.170.
  28. Segerer S, Nelson PJ, Schlöndorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol. 2000;11(1):152–76.
  29. Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016;29(5): 611–6. doi: 10.1007/s40620-016-0309-2.
  30. Kasiske BL, Keane WF. Laboratory assesment of renal biopsy. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu AS. Brenner and Rector's the Kidney. 10th edition. Elsevier; 2016. p. 1137–74.
  31. Walker PD. The renal biopsy. Arch Pathol Lab Med. 2009;133(2):181–8. doi: 10.1043/1543- 2165-133.2.181.
  32. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545–53. doi: 10.1111/j.1365- 2036.2007.03407.x.
  33. Батюшин ММ, Дмитриева ОВ, Терентьев ВП. Роль анальгетиков и нестероидных противовоспалительных препаратов в развитии интерстициального поражения почек. Нефрология и диализ. 2006;8(3):239–43.
  34. Pirani CL, Valeri A, D'Agati V, Appel GB. Renal toxicity of nonsteroidal anti-inflammatory drugs. Contrib Nephrol. 1987;55:159–75.
  35. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 1993;44(3):643–53. doi: 10.1038/ki.1993.293.
  36. Чельцов ВВ. НПВС-нефропатии. Клиническая нефрология. 2011;(5):17–23.
  37. Radford MG Jr, Holley KE, Grande JP, Larson TS, Wagoner RD, Donadio JV, McCarthy JT. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA. 1996;276(6):466–9.
  38. Simpson IJ, Marshall MR, Pilmore H, Manley P, Williams L, Thein H, Voss D. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11(5):381–5. doi: 10.1111/j.1440- 1797.2006.00651.x.
  39. Ruffenach SJ, Siskind MS, Lien YH. Acute interstitial nephritis due to omeprazole. Am J Med. 1992;93(4):472–3. doi: 10.1016/0002- 9343(92)90181-A.
  40. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013;14:150. doi: 10.1186/1471-2369-14-150.
  41. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837–44. doi: 10.1038/ki.2014.74.
  42. Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, Paterson JM, Juurlink DN. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3(2):E166–71. doi: 10.9778/cmajo.20140074.
  43. Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, Nasr SH. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int. 2015;87(2): 458–64. doi: 10.1038/ki.2014.294.
  44. Plakogiannis R, Nogid A. Acute interstitial nephritis associated with coadministration of vancomycin and ceftriaxone: case series and review of the literature. Pharmacotherapy. 2007;27(10):1456–61. doi: 10.1592/ phco.27.10.1456.
  45. Pirani CL, Valeri A, D'Agati V, Appel GB. Renal toxicity of nonsteroidal anti-inflammatory drugs. Contrib Nephrol. 1987;55:159–75. doi: 10.1159/000413416.
  46. Zaigraykin N, Kovalev J, Elias N, Naschitz JE. Levofloxacin-induced interstitial nephritis and vasculitis in an elderly woman. Isr Med Assoc J. 2006;8(10):726–7.
  47. Chatzikyrkou C, Hamwi I, Clajus C, Becker J, Hafer C, Kielstein JT. Biopsy proven acute interstitial nephritis after treatment with moxifloxacin. BMC Nephrol. 2010;11:19. doi: 10.1186/1471-2369-11-19.
  48. Schubert C, Bates WD, Moosa MR. Acute tubulointerstitial nephritis related to antituberculous drug therapy. Clin Nephrol. 2010;73(6): 413–9. doi: 10.5414/CNP73413.
  49. Robson M, Levi J, Dolberg L, Rosenfeld JB. Acute tubulo-interstitial nephritis following sulfadiazine therapy. Isr J Med Sci. 1970;6(4): 561–6.
  50. Htike NL, Santoro J, Gilbert B, Elfenbein IB, Teehan G. Biopsy-proven vancomycin-associated interstitial nephritis and acute tubular necrosis. Clin Exp Nephrol. 2012;16(2):320–4. doi: 10.1007/s10157-011-0559-1.
  51. Сигитова ОН, Архипов ЕВ. Тубулоинтерстициальный нефрит. Вестник современной клинической медицины. 2010;3(3):45–9.
  52. Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77(11):956–61. doi: 10.1038/ki.2010.89.
  53. González E, Gutiérrez E, Galeano C, Chevia C, de Sequera P, Bernis C, Parra EG, Delgado R, Sanz M, Ortiz M, Goicoechea M, Quereda C, Olea T, Bouarich H, Hernández Y, Segovia B, Praga M; Grupo Madrileño De Nefritis Intersticiales. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940–6. doi: 10.1038/sj. ki.5002776.
  54. Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, Nasr SH. Biopsy-proven acute interstitial nephritis, 1993–2011: a case series. Am J Kidney Dis. 2014;64(4):558–66. doi: 10.1053/j.ajkd.2014.04.027.
  55. Preddie DC, Markowitz GS, Radhakrishnan J, Nickolas TL, D'Agati VD, Schwimmer JA, Gardenswartz M, Rosen R, Appel GB. Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol. 2006;1(4): 718–22. doi: 10.2215/CJN.01711105.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Dyadyk A.I., Kugler T.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies